|Implementation period||11.03.2019. – 10.03.2023.|
|Management Committee member||Dr. Nadezda Romancikova|
|Substitute Management Committee member||Dr. Edijs Vavers|
|Project web page||https://ernest-gpcr.eu/the-action/|
All cells face the vital challenge of sensing their environments and responding in appropriate ways. This process is accomplished by transmembrane signal transduction, which is present in every species and governs every aspect of how an organism functions.
In regard to human health, there is a huge drive to understand how transmembrane signal transduction networks function on the molecular, cellular and physiological level so that drugs can be designed to modulate different aspects of the signal transduction cascade in highly specific ways.
Despite significant progress in understanding the individual components, signal transduction as a whole is not fully understood. Fundamental questions remain regarding how different signalling pathways are activated and modulated in precise and reproducible ways. Filling this gap in knowledge is absolutely necessary to advance the next generation of drugs that will achieve therapeutic efficacy while minimizing side effects.
A prime example of this research challenge is the large family of G protein-coupled receptors (GPCRs), which are the target of more than a third of all marketed drugs. The COST Action ERNEST (European Research Network on Signal Transduction) will tackle this challenge by uniting scientists from different disciplines spanning the molecular, cellular, physiological, and clinical perspectives.
This network of diverse investigators will be uniquely able to synergistically develop an unprecedented comprehensive understanding of signal transduction that will advance drug design efforts in Europe, for the benefit of societies and human health worldwide.
More information can be found at the: https://www.cost.eu/actions/CA18133/#tabs|Name:overview